These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1308 related articles for article (PubMed ID: 27771475)

  • 1. The safety of intrauterine devices among young women: a systematic review.
    Jatlaoui TC; Riley HEM; Curtis KM
    Contraception; 2017 Jan; 95(1):17-39. PubMed ID: 27771475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 3-year multicentre randomized controlled trial of etonogestrel- and levonorgestrel-releasing contraceptive implants, with non-randomized matched copper-intrauterine device controls.
    Bahamondes L; Brache V; Meirik O; Ali M; Habib N; Landoulsi S;
    Hum Reprod; 2015 Nov; 30(11):2527-38. PubMed ID: 26409014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intrauterine devices: an effective alternative to oral hormonal contraception.
    Prescrire Int; 2009 Jun; 18(101):125-30. PubMed ID: 19637436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The safety of intrauterine devices in breastfeeding women: a systematic review.
    Berry-Bibee EN; Tepper NK; Jatlaoui TC; Whiteman MK; Jamieson DJ; Curtis KM
    Contraception; 2016 Dec; 94(6):725-738. PubMed ID: 27421765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An evaluation of the levonorgestrel-releasing IUD: its advantages and disadvantages when compared to the copper-releasing IUDs.
    Chi IC
    Contraception; 1991 Dec; 44(6):573-88. PubMed ID: 1773615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intrauterine device use among women with uterine fibroids: a systematic review.
    Zapata LB; Whiteman MK; Tepper NK; Jamieson DJ; Marchbanks PA; Curtis KM
    Contraception; 2010 Jul; 82(1):41-55. PubMed ID: 20682142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hormonally impregnated intrauterine systems (IUSs) versus other forms of reversible contraceptives as effective methods of preventing pregnancy.
    French R; Van Vliet H; Cowan F; Mansour D; Morris S; Hughes D; Robinson A; Proctor T; Summerbell C; Logan S; Helmerhorst F; Guillebaud J
    Cochrane Database Syst Rev; 2004; 2004(3):CD001776. PubMed ID: 15266453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized clinical trial of the effect of intensive versus non-intensive counselling on discontinuation rates due to bleeding disturbances of three long-acting reversible contraceptives.
    Modesto W; Bahamondes MV; Bahamondes L
    Hum Reprod; 2014 Jul; 29(7):1393-9. PubMed ID: 24812309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hormonal intrauterine devices.
    Rybo G; Andersson K; Odlind V
    Ann Med; 1993 Apr; 25(2):143-7. PubMed ID: 8489751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative contraceptive effectiveness of levonorgestrel-releasing and copper intrauterine devices: the European Active Surveillance Study for Intrauterine Devices.
    Heinemann K; Reed S; Moehner S; Minh TD
    Contraception; 2015 Apr; 91(4):280-3. PubMed ID: 25601350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hormonally impregnated intrauterine systems (IUSs), versus other forms of reversible contraceptives as effective methods of preventing pregnancy.
    French R; Cowan F; Mansour D; Morris S; Hughes D; Robinson A; Proctor T; Summerbell C; Logan S; Guillebaud J
    Cochrane Database Syst Rev; 2001; (2):CD001776. PubMed ID: 11406007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Menstrual characteristics and ultrasonographic uterine cavity measurements predict bleeding and pain in nulligravid women using intrauterine contraception.
    Kaislasuo J; Heikinheimo O; Lähteenmäki P; Suhonen S
    Hum Reprod; 2015 Jul; 30(7):1580-8. PubMed ID: 25990577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progestin intrauterine devices versus copper intrauterine devices for emergency contraception.
    Ramanadhan S; Goldstuck N; Henderson JT; Che Y; Cleland K; Dodge LE; Edelman A
    Cochrane Database Syst Rev; 2023 Feb; 2(2):CD013744. PubMed ID: 36847591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hormonal and intrauterine methods for contraception for women aged 25 years and younger.
    Krashin J; Tang JH; Mody S; Lopez LM
    Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD009805. PubMed ID: 26280888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Twelve-month contraceptive continuation and repeat pregnancy among young mothers choosing postdelivery contraceptive implants or postplacental intrauterine devices.
    Cohen R; Sheeder J; Arango N; Teal SB; Tocce K
    Contraception; 2016 Feb; 93(2):178-83. PubMed ID: 26475368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two years of intrauterine contraception with levonorgestrel and with copper: a randomized comparison of the TCu 380Ag and levonorgestrel 20 mcg/day devices.
    Sivin I; Stern J; Diaz J; Diaz MM; Faundes A; el Mahgoub S; Diaz S; Pavez M; Coutinho E; Mattos CE
    Contraception; 1987 Mar; 35(3):245-55. PubMed ID: 3111785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Canadian Contraception Consensus (Part 3 of 4): Chapter 7--Intrauterine Contraception.
    Black A; Guilbert E; Costescu D; Dunn S; Fisher W; Kives S; Mirosh M; Norman W; Pymar H; Reid R; Roy G; Varto H; Waddington A; Wagner MS; Whelan AM; Mansouri S
    J Obstet Gynaecol Can; 2016 Feb; 38(2):182-222. PubMed ID: 27032746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of levonorgestrel 52 mg intrauterine system compared to copper intrauterine device: a population-based cohort study.
    Bosco-Lévy P; Gouverneur A; Langlade C; Miremont G; Pariente A
    Contraception; 2019 Jun; 99(6):345-349. PubMed ID: 30871933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intrauterine Contraception Continuation in Adolescents and Young Women: A Systematic Review.
    Usinger KM; Gola SB; Weis M; Smaldone A
    J Pediatr Adolesc Gynecol; 2016 Dec; 29(6):659-667. PubMed ID: 27386754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extended use up to 5 years of the etonogestrel-releasing subdermal contraceptive implant: comparison to levonorgestrel-releasing subdermal implant.
    Ali M; Akin A; Bahamondes L; Brache V; Habib N; Landoulsi S; Hubacher D;
    Hum Reprod; 2016 Nov; 31(11):2491-2498. PubMed ID: 27671673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 66.